Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs State Street SPDR S&P Biotech ETF — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.91 (market cap $3.56B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.8× GraniteShares 2x Long NVDA Daily ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 9,740,643). Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NVDL | XBI | |
|---|---|---|
Market Cap | $3.56B | $10.11B |
Volume | 9,740,643 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $43.02 | $169.55 |
52-Week Low | $21.76 | $104.99 |
Typical Hold Time | 15 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.905, down 6.73% on the day, with technical indicators showing a bullish bias from moving averages but neutral oscillators. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to lead AI innovation and recently beat Q2 2027 earnings estimates. Support levels are clustered around $36-$34, with resistance at $38-$41.
While leveraged exposure to NVIDIA's AI leadership offers significant upside potential, NVDL faces risks from daily reset mechanics that can cause performance drift from long-term NVDA returns. Recent articles highlight both optimism about NVIDIA's technical breakout and concerns about the ETF's tracking efficiency. The bullish technical setup suggests near-term opportunity, but volatility remains elevated.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
